Menu Back toPost COVID: Sites Evolving Role in the Clinical Trial Ecosystem

DIA 2021 Global Annual Meeting

Post COVID: Sites Evolving Role in the Clinical Trial Ecosystem

Session Chair(s)

Cristin  MacDonald, PhD

Cristin MacDonald, PhD

  • Vice President, Client Delivery
  • WCG Avoca, United States
Following COVID-19, there is a changing role for Sites in the decision-making framework for the selection, implementation, and use of various technologies for clinical trial execution. We will discuss how Sponsors, CROs and Sites can move forward.
Learning Objective : Review the rapid response working group findings as it related to site execution and monitoring during the COVID-pandemic; Discuss how COVID-19 impacted traditional clinical trial execution decision making from dictating to sites how to conduct the research, to including/listening to sites for appropriate next steps; Identify how technology adoption in clinical trial execution will be decided upon.


Greg  Tuyteleers


Greg Tuyteleers

  • Global Operations Head Managed Access and Global Lead Decentralized Trials
  • Janssen, Belgium
Liz  Rogers, MSc


Liz Rogers, MSc

  • Vice President, Head of Global Site and Study Operations
  • Pfizer Inc, United States
Andy  Lee, MA


Andy Lee, MA

  • Senior Vice President, Head of Global Clinical Trial Operations
  • Merck & Co., Inc., United States
Sandy  Smith


Sandy Smith

  • SVP Clinical Solutions and Strategic Partnerships
  • WCG Cinical, United States